SLC5A2 and type 2 diabetes mellitus: There are ~500,000 patients in the UK currently taking an SGLT2 Inhibitor for diabetes control, therefore it stands that ~12% of all T2DM patients in the UK are taking an SGLT2 Inhibitor (26).